Prostate-specific antigen or human kallikrein 3? Recent developments.
Diamandis
E P
EP
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Ont., Canada. ediamandis@mtsinai.on.ca
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000517:prevention & control; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D001941:Breast Diseases / Q000175:diagnosis*; D001943:Breast Neoplasms / Q000378:metabolism; D005260:Female; D006801:Humans; D007610:Kallikreins / Q000032:analysis*; D008297:Male; D008403:Mass Screening; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000032:analysis* / Q000096:biosynthesis / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000517:prevention & control; D009626:Terminology as Topic; D014407:Tumor Cells, Cultured
D014408:Biomarkers, Tumor; D007610:Kallikreins; D017430:Prostate-Specific Antigen